Tocilizumab

Generic Name: Tocilizumab

Brand Names: Actemra, RoActemra, Tyenne, Tofidence

Drug Type: Biotech

Chemical Formula: -

CAS Number: 375823-41-9

Unique Ingredient Identifier: I031V2H011

Background: Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication: Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: Monotherapy

Clinical Trials

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cevostamab
Drug: Tocilizumab
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Daratumumab

First Posted Date: 2021-06-02

Last Posted Date: 2024-12-16

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 126

Registration Number: NCT04910568

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
City of Hope - Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States

and more 31 locations

Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study

Completed

Conditions: Tocilizumab
Mortality
Critical Care
COVID-19

Interventions: Drug: Tocilizumab

First Posted Date: 2021-05-19

Last Posted Date: 2021-05-20

Lead Sponsor: Karadeniz Technical University

Target Recruit Count: 213

Registration Number: NCT04893031

Locations: 🇹🇷
Karadeniz Technical University, Trabzon, Turkey

Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement

Phase 3

Recruiting

Conditions: Neurovascular Disorder
Giant Cell Arteritis

Interventions: Drug: Placebo
Drug: Tocilizumab

First Posted Date: 2021-05-17

Last Posted Date: 2024-07-31

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 66

Registration Number: NCT04888221

Locations: 🇫🇷
Saint Antoine Hospital, Neurology Unit, Assistance Publique-Hôpitaux de Paris, Paris, France

Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: traditional Covid -19 therapy
Drug: Tocilizumab

First Posted Date: 2021-05-04

Last Posted Date: 2022-11-01

Lead Sponsor: Beni-Suef University

Target Recruit Count: 100

Registration Number: NCT04871854

Locations: 🇪🇬
ALsafwa specialized hospital, Fayoum, Egypt

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis

Phase 2

Not yet recruiting

Conditions: Granulomatosis With Polyangiitis
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions: Drug: Rituximab
Drug: Tocilizumab
Drug: Abatacept

First Posted Date: 2021-05-04

Last Posted Date: 2023-02-08

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 42

Registration Number: NCT04871191

Locations: 🇫🇷
Hôpital de la Croix Saint Simon, Paris, France

Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis

Phase 1

Terminated

Conditions: Interaction
Arthritis, Rheumatoid

Interventions: Drug: Tocilizumab
Drug: Sarilumab

First Posted Date: 2021-04-13

Last Posted Date: 2023-01-25

Lead Sponsor: University of Southern Denmark

Target Recruit Count: 3

Registration Number: NCT04842981

Locations: 🇩🇰
Odense University Hospital, Odense, Region Of Southern Denmark, Denmark
🇩🇰
Danish Hospital for Rheumatic Diseases, Sønderborg, Region Of Southern Denmark, Denmark
🇩🇰
Hospital South West Jutland, Esbjerg, Region Of Southern Denmark, Denmark